Skip to main content

Table 4 Clinical trials for treating the HER2 mutation positive patients by irreversible pan-ErbB tyrosine kinase inhibitor (Neratinib; HKI-272). Tables and data are adopted from clinicaltrials.gov. (https://clinicaltrials.gov/)

From: Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

Status of trail

Condition

Interventions of clinical trial

Phase

Completion time

Completed

• BC

• Advanced solid tumors

• Drug: Neratinib and vinorelbine

Phases 1 and 2

2018

Completed

• Breast neoplasms

• Drug: Neratinib

Phase 2

2018

Completed

• Advanced BC

• Drug: HKI-272 and trastuzumab

Phases 1 and 2

2018

Completed

• Advanced BC

• Advanced solid tumors, breast neoplasms

• Drug: HKI-272 and paclitaxel

Phases 1 and 2

2018

Active, not recruiting

• BC

• Drug: Neratinib and placebo

Phase 3

2020

Completed

• BC

• Drug: Neratinib and capecitabine

Phases 1 and 2

–

Recruiting

• BC

• Drug: HKI-272, Capecitabine, Ado Trastuzumab Emtansine

Phase 2

2023

Completed

• Breast neoplasms

• Drug: Neratinib

Phase 1

2007

Completed

• BC

• Drug: Neratinib, trastuzumab and paclitaxel

Phase 2

2018

Completed

• Advanced BC

• BC

• Drug: Neratinib, lapatinib and capecitabine

Phase 2

2018

Completed

• BC

• Drug: Temsirolimus and neratinib

Phases 1 and 2

2016